Journal of evaluation in clinical practice
-
Biologics are substantially more expensive than their conventional counterparts but it is unclear whether extra costs deliver better health outcomes. We compare clinical and economic outcomes between teriparatide (monthly costs $1120) and bisphosphonates (monthly costs $14) among postmenopausal women with osteoporosis. ⋯ The biological agent, teriparatide, is more expensive yet less effective than conventional treatment, bisphosphonates.
-
In rheumatic disorders, one of the treatment objectives is to improve the patient's quality of life (QoL). Similar to other chronic conditions, drug compliance is poor, but necessary for successful treatment. The relationship between drug compliance and QoL has never been tested. The aim of this study was to elucidate the relationship between drug compliance and QoL in patients with different rheumatic disorders. ⋯ Doctors caring for rheumatic patients should focus their efforts on strengthening drug compliance in patients with higher QoL where it seems that lower compliance is more likely.
-
Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage non-small cell lung cancer (NSCLC) patients. Therefore, access to such medical innovations in time is critical for patients with the right indications. The aim of this study was to explore determinants of the adoption of MTD among NSCLC patients under Taiwan's National Health Insurance (NHI) system. ⋯ Our findings suggest that both patient- and hospital-level characteristics significantly affected the adoption of MTD among NSCLC patients.
-
In the United States, cardiovascular disease (CVD) is the leading cause of death. The US Centers for Disease Control and Prevention contracted an evaluation of the Aggressively Treating Global Cardiometabolic Risk Factors to Reduce Cardiovascular Events (AT GOAL) programme as part of its effort to identify strategies to address CVD risk factors. ⋯ Findings from the AT GOAL evaluation support the value of a facilitated quality improvement (QI) initiative on managing CVD risk.